| Ytd | -35.57% | |
| 1y | -33.79% |
| Open | 5.26 | Prev Close | 5.25 | Low | 5.21 | High | 5.50 | Mkt Cap | 197.67M |
| Vol | 382.88K | Avg Vol | 255.88K | EPS | -1.27 | P/E | N/A | Forward P/E | -9.90 |
| Beta | 0.94 | Short Ratio | 11.20 | Inst. Own | 69.84% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 5.13 | 200-d Avg | 6.51 | 1yr Est | 8.00 |
LFCR News
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Ou
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Inject
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 millio
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the an
Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Ou
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contrac
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.16) per share. This is a 20 perce
Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Marke
Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed g
Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $120.000 million-$125.000 million vs $129.846
Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered wi
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract developmen
Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $74.000 million-$76.000 million
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.29) per share which beat the anal
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract developmen
Keybanc analyst Paul Knight initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Sector
Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $74.000 million-$76.000 million vs $127.802 m
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.06) per share which beat the anal
Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract developmen
William Blair analyst Max Smock initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Ou
Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.47) per share which missed the an
The most overbought stocks in the consumer staples sector presents an opportunity to go short on the
On Friday, 497 companies set new 52-week lows.
On Thursday, 63 companies set new 52-week lows.
The most oversold stocks in the consumer staples sector presents an opportunity to buy into underval
During Friday's trading, 293 companies set new 52-week lows.
On Thursday, 241 companies hit new 52-week lows.